UAMC3203

CAS No. 2271358-64-4

UAMC3203( UAMC 3203 | UAMC-3203 )

Catalog No. M20094 CAS No. 2271358-64-4

UAMC-3203 is a potent and selective Ferroptosis inhibitor (IC50: 12 nM).

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 63 In Stock
10MG 101 In Stock
25MG 169 In Stock
50MG 255 In Stock
100MG 380 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    UAMC3203
  • Note
    Research use only, not for human use.
  • Brief Description
    UAMC-3203 is a potent and selective Ferroptosis inhibitor (IC50: 12 nM).
  • Description
    UAMC-3203 is a potent and selective Ferroptosis inhibitor (IC50: 12 nM).
  • In Vitro
    ——
  • In Vivo
    No toxicity is observed in mice after repeated injections of UAMC-3203 (20 μmol/kg; injected intraperitoneally; daily, over a period of 4 weeks). Animal Model:Wild type mice derived from a Gpx4 fl/fl breeding Dosage:20 μmol/kg Administration:Injected intraperitoneally; daily, over a period of 4 weeks Result:No toxicity was observed.
  • Synonyms
    UAMC 3203 | UAMC-3203
  • Pathway
    Apoptosis
  • Target
    Ferroptosis
  • Recptor
    Ferroptosis
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2271358-64-4
  • Formula Weight
    471.66
  • Molecular Formula
    C25H37N5O2S
  • Purity
    >98% (HPLC)
  • Solubility
    DMSO:199.3 mM
  • SMILES
    O=S(=O)(NCCN1CCNCC1)c1ccc(NC2CCCCC2)c(NCc2ccccc2)c1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Devisscher L et al. Discovery of Novel Drug-Like Ferroptosis Inhibitors with in Vivo Efficacy. J Med Chem. 2018 Nov 21;61(22):10126-10140.
molnova catalog
related products
  • ROS-generating?agent...

    Ros-generating agent 1 has anticancer activity and generates ROS by covalently modifying Sec-498 residues of TrxR.

  • PRLX-93936 HCL

    PRLX-93936 HCL is an analog of erastin and demonstrated synergistic effects against non-small cell lung cancer (NSCLC) cells with cisplatin.

  • SRS16-86

    SRS16-86 is a novel third-generation ferrostatin, is an inhibitor of?ferroptosis.